Endonovo Therapeutics Inc (ENDV)

[Craig305]

Form 10-Q Discussion.

I am surprised nobody is mentioning anything about the 10-Q.
Not much to discuss other than dilution of shares it seems.
Consulting services have increased with the payments coming from equity shares. I suppose these consultants might be the "new" employees (VP, Marketing Mgr) and who knows what else.
The Consulting expense increased from $35K in Q1 to $148K in Q2...all paid via common shares issued.

Or their payment is coming from stock options.

Something new that was not on the 1Q 10-Q is the mention of Stock Options.
Stock Options were granted to independent contractors exercisable into up to 19,250,000 shares of common stock. They have an exercise price of $0.054/share
None were exercised in Q2. They were most likely issued towards the end of the quarter. It seems that's when the "new" employees (or should we call them "contractors"?) showed up on the LinkedIn page.